Evofem Biosciences PE Ratio 2013-2022 | EVFM

Current and historical p/e ratio for Evofem Biosciences (EVFM) from 2013 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evofem Biosciences PE ratio as of May 20, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Evofem Biosciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-23 0.41 0.00
2022-03-31 5.10 $-19.07 0.00
2021-12-31 5.63 $-24.59 0.00
2021-09-30 11.08 $-27.14 0.00
2021-06-30 16.95 $-25.49 0.00
2021-03-31 26.25 $-35.08 0.00
2020-12-31 36.15 $-32.68 0.00
2020-09-30 35.40 $-29.24 0.00
2020-06-30 42.45 $-28.19 0.00
2020-03-31 79.80 $-29.09 0.00
2019-12-31 92.55 $-33.13 0.00
2019-09-30 75.60 $-37.78 0.00
2019-06-30 99.60 $-43.93 0.00
2019-03-31 52.50 $-46.03 0.00
2018-12-31 62.85 $-105.25 0.00
2018-09-30 60.75 $-96.55 0.00
2018-06-30 40.65 $-97.60 0.00
2018-03-31 95.25 $-98.94 0.00
2017-12-31 175.50 $-49.47 0.00
2017-09-30 42.30 $-62.06 0.00
2017-06-30 48.60 $-65.65 0.00
2017-03-31 144.00 $-64.75 0.00
2016-12-31 100.80 $-84.54 0.00
2016-09-30 100.80 $-134.01 0.00
2016-06-30 88.19 $-232.04 0.00
2016-03-31 54.90 $-277.01 0.00
2015-12-31 125.10 $-282.40 0.00
2015-09-30 726.30 $-260.82 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.005B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00